候选疫苗-话题@MedSci

#候选疫苗#

43篇内容 | 1510人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1937305, encodeId=27d3193e305e2, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=阿斯利康的COVID-19候选疫苗：有效率达70％, objectType=article, longId=203678, objectId=d9f82036e8c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9f82036e8c7, replyNumber=0, likeNumber=61, createdTime=2021-04-11, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9f82036e8c7, moduleTitle=阿斯利康的COVID-19候选疫苗：有效率达70％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9f82036e8c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937308, encodeId=6089193e30816, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=COVID-19候选疫苗SN14将进入临床试验, objectType=article, longId=204716, objectId=42a1204e16be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=42a1204e16be, replyNumber=0, likeNumber=53, createdTime=2021-09-02, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=42a1204e16be, moduleTitle=COVID-19候选疫苗SN14将进入临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=42a1204e16be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937291, encodeId=04a4193e291f3, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=CureVac的COVID-19候选疫苗可触发免疫反应, objectType=article, longId=194238, objectId=482b194238a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=482b194238a0, replyNumber=0, likeNumber=59, createdTime=2020-07-04, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=482b194238a0, moduleTitle=CureVac的COVID-19候选疫苗可触发免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=482b194238a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937293, encodeId=ee44193e29311, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=默克携两款候选疫苗加入COVID-19疫苗竞赛, objectType=article, longId=194854, objectId=63d01948541e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63d01948541e, replyNumber=0, likeNumber=60, createdTime=2020-09-18, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63d01948541e, moduleTitle=默克携两款候选疫苗加入COVID-19疫苗竞赛, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63d01948541e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937296, encodeId=c664193e2962f, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=NEJM：Moderna的COVID-19候选疫苗在所有受试者中诱导了强烈的免疫应答, objectType=article, longId=197569, objectId=a86319e569b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a86319e569b8, replyNumber=0, likeNumber=136, createdTime=2020-12-13, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a86319e569b8, moduleTitle=NEJM：Moderna的COVID-19候选疫苗在所有受试者中诱导了强烈的免疫应答, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a86319e569b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937292, encodeId=f2a2193e2928a, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=Novavax启动COVID-19候选疫苗NVX-CoV2373的I / II期试验, objectType=article, longId=194739, objectId=c5e8194e39ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5e8194e39ed, replyNumber=0, likeNumber=53, createdTime=2021-03-28, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5e8194e39ed, moduleTitle=Novavax启动COVID-19候选疫苗NVX-CoV2373的I / II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5e8194e39ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937298, encodeId=8d1f193e298d7, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=NEJM：COVID-19候选疫苗mRNA-1273的临床前研究，效果明显！, objectType=article, longId=198318, objectId=b1ae19831868, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1ae19831868, replyNumber=0, likeNumber=57, createdTime=2021-01-15, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1ae19831868, moduleTitle=NEJM：COVID-19候选疫苗mRNA-1273的临床前研究，效果明显！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1ae19831868)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937287, encodeId=0abb193e287b4, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=COVID-19候选疫苗（PittCoVacc，匹兹堡冠状病毒疫苗）：动物实验显成效, objectType=article, longId=191370, objectId=03ee1913e086, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03ee1913e086, replyNumber=0, likeNumber=56, createdTime=2020-11-12, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03ee1913e086, moduleTitle=COVID-19候选疫苗（PittCoVacc，匹兹堡冠状病毒疫苗）：动物实验显成效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03ee1913e086)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937289, encodeId=e7d9193e2898e, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=bioRxiv：一种COVID-19候选疫苗在恒河猴体内试验成功了!, objectType=article, longId=192896, objectId=b3881928967f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3881928967f, replyNumber=0, likeNumber=72, createdTime=2021-03-04, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3881928967f, moduleTitle=bioRxiv：一种COVID-19候选疫苗在恒河猴体内试验成功了!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3881928967f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937290, encodeId=a5a7193e29076, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=Moderna的新冠病毒候选疫苗mRNA-1273，获得FDA批准进行II期临床研究, objectType=article, longId=193802, objectId=898d1938022e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=898d1938022e, replyNumber=0, likeNumber=62, createdTime=2020-11-12, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=898d1938022e, moduleTitle=Moderna的新冠病毒候选疫苗mRNA-1273，获得FDA批准进行II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=898d1938022e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937297, encodeId=7b34193e29741, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=COVID-19候选疫苗mRNA-1273的III临床试验：规模将继续扩大, objectType=article, longId=198171, objectId=c8e91981e1ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8e91981e1ab, replyNumber=0, likeNumber=71, createdTime=2021-07-01, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8e91981e1ab, moduleTitle=COVID-19候选疫苗mRNA-1273的III临床试验：规模将继续扩大, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8e91981e1ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937299, encodeId=f498193e29942, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=强生旗下COVID-19候选疫苗Ad26.COV2.S：即将开展I/IIa期临床研究, objectType=article, longId=198422, objectId=d19d19842276, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d19d19842276, replyNumber=0, likeNumber=69, createdTime=2021-01-31, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d19d19842276, moduleTitle=强生旗下COVID-19候选疫苗Ad26.COV2.S：即将开展I/IIa期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d19d19842276)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937294, encodeId=a392193e2940b, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=CELL：我国研究人员开发出新冠候选疫苗，并可量产, objectType=article, longId=195436, objectId=b7bd19543698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7bd19543698, replyNumber=0, likeNumber=75, createdTime=2020-09-16, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7bd19543698, moduleTitle=CELL：我国研究人员开发出新冠候选疫苗，并可量产, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7bd19543698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937286, encodeId=485d193e286c5, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=强生表示，针对新冠COVID-19候选疫苗的临床试验最迟于9月开始，预计2021年初正式上市使用, objectType=article, longId=191234, objectId=1a0e1912345a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1a0e1912345a, replyNumber=0, likeNumber=64, createdTime=2021-01-13, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1a0e1912345a, moduleTitle=强生表示，针对新冠COVID-19候选疫苗的临床试验最迟于9月开始，预计2021年初正式上市使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1a0e1912345a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937288, encodeId=1b9d193e288e5, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=EBioMedicine：新冠候选疫苗初见成效，即将进入临床试验阶段！, objectType=article, longId=191410, objectId=e0b71914103a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0b71914103a, replyNumber=0, likeNumber=80, createdTime=2020-12-11, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0b71914103a, moduleTitle=EBioMedicine：新冠候选疫苗初见成效，即将进入临床试验阶段！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0b71914103a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937284, encodeId=c485193e284df, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=第68届ASTMH年会：登革热候选疫苗关键III期试验的18个月数据, objectType=article, longId=183562, objectId=963318356294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=963318356294, replyNumber=0, likeNumber=65, createdTime=2020-09-30, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=963318356294, moduleTitle=第68届ASTMH年会：登革热候选疫苗关键III期试验的18个月数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=963318356294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937282, encodeId=a8b0193e28274, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=J Virol：中国和美国的科学家联合开发出制备登革热候选疫苗毒株的方法, objectType=article, longId=152322, objectId=dfc015232247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dfc015232247, replyNumber=0, likeNumber=55, createdTime=2019-02-04, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dfc015232247, moduleTitle=J Virol：中国和美国的科学家联合开发出制备登革热候选疫苗毒株的方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dfc015232247)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937283, encodeId=4614193e2839d, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=我国科学家创制了非洲猪瘟候选疫苗, objectType=article, longId=166773, objectId=4dcc166e7364, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4dcc166e7364, replyNumber=0, likeNumber=73, createdTime=2020-02-14, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4dcc166e7364, moduleTitle=我国科学家创制了非洲猪瘟候选疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4dcc166e7364)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937281, encodeId=8283193e28106, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=Lancet：重大进展！新的HIV候选疫苗可安全地在健康人和猴子中诱导出强效的免疫反应, objectType=article, longId=142794, objectId=2a76142e9452, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a76142e9452, replyNumber=0, likeNumber=87, createdTime=2019-03-20, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a76142e9452, moduleTitle=Lancet：重大进展！新的HIV候选疫苗可安全地在健康人和猴子中诱导出强效的免疫反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a76142e9452)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1937279, encodeId=48d0193e27998, content=<a href='/topic/show?id=d6262e4688b' target=_blank style='color:#2F92EE;'>#候选疫苗#</a>, objectTitle=Science：科学家开发出候选疫苗成功抵御MERS的感染, objectType=article, longId=60920, objectId=cb5b60920f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb5b60920f7, replyNumber=0, likeNumber=74, createdTime=2016-06-25, rootId=0, userName=12498f17m66暂无昵称, userId=e5742500212, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb5b60920f7, moduleTitle=Science：科学家开发出候选疫苗成功抵御MERS的感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb5b60920f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

候选疫苗

2020-05-29

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

阿斯利康的COVID-19候选疫苗：有效率达70％

2021-04-11

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

COVID-19候选疫苗SN14将进入临床试验

2021-09-02

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

CureVac的COVID-19候选疫苗可触发免疫反应

2020-07-04

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

默克携两款候选疫苗加入COVID-19疫苗竞赛

2020-09-18

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

NEJM：Moderna的COVID-19候选疫苗在所有受试者中诱导了强烈的免疫应答

2020-12-13

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

Novavax启动COVID-19候选疫苗NVX-CoV2373的I / II期试验

2021-03-28

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

NEJM：COVID-19候选疫苗mRNA-1273的临床前研究，效果明显！

2021-01-15

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

COVID-19候选疫苗（PittCoVacc，匹兹堡冠状病毒疫苗）：动物实验显成效

2020-11-12

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

bioRxiv：一种COVID-19候选疫苗在恒河猴体内试验成功了!

2021-03-04

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

Moderna的新冠病毒候选疫苗mRNA-1273，获得FDA批准进行II期临床研究

2020-11-12

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

COVID-19候选疫苗mRNA-1273的III临床试验：规模将继续扩大

2021-07-01

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

强生旗下COVID-19候选疫苗Ad26.COV2.S：即将开展I/IIa期临床研究

2021-01-31

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

CELL：我国研究人员开发出新冠候选疫苗，并可量产

2020-09-16

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

强生表示，针对新冠COVID-19候选疫苗的临床试验最迟于9月开始，预计2021年初正式上市使用

2021-01-13

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

EBioMedicine：新冠候选疫苗初见成效，即将进入临床试验阶段！

2020-12-11

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

第68届ASTMH年会：登革热候选疫苗关键III期试验的18个月数据

2020-09-30

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

J Virol：中国和美国的科学家联合开发出制备登革热候选疫苗毒株的方法

2019-02-04

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

我国科学家创制了非洲猪瘟候选疫苗

2020-02-14

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

Lancet：重大进展！新的HIV候选疫苗可安全地在健康人和猴子中诱导出强效的免疫反应

2019-03-20

12498f17m66暂无昵称 (审核中...)

前往app查看评论内容

#候选疫苗#

Science：科学家开发出候选疫苗成功抵御MERS的感染

2016-06-25

科室
- - 订阅+
  - 更多科室
工具
服务